Mediwound Ltd
F:M8W
Mediwound Ltd
MediWound Ltd. is a biopharmaceutical company engaging in the development, manufacture, and commercialization of products to address needs in the fields of severe burns, chronic wounds, and other hard-to-heal wounds. The firm focuses on developing, manufacturing and commercializing therapeutics products in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders and other indications. The firm's product, NexoBrid, is indicated for the removal of dead or damaged tissue, known as eschar, in adults with deep partial- and full-thickness thermal burns, also referred to as severe burns. The firm sells NexoBrid in Europe and Israel. NexoBrid is a topically-applied product that removes eschar in four hours without harming the surrounding healthy tissues. Its product, EscharEx, is a topical biological drug, which is being developed for debridement of chronic and other hard-to-heal wounds. NexoBrid and EscharEx are based on its proteolytic enzyme technology. The firm is also developing an injectable product based on its proteolytic enzyme technology for connective tissue pathologies and indications.
MediWound Ltd. is a biopharmaceutical company engaging in the development, manufacture, and commercialization of products to address needs in the fields of severe burns, chronic wounds, and other hard-to-heal wounds. The firm focuses on developing, manufacturing and commercializing therapeutics products in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders and other indications. The firm's product, NexoBrid, is indicated for the removal of dead or damaged tissue, known as eschar, in adults with deep partial- and full-thickness thermal burns, also referred to as severe burns. The firm sells NexoBrid in Europe and Israel. NexoBrid is a topically-applied product that removes eschar in four hours without harming the surrounding healthy tissues. Its product, EscharEx, is a topical biological drug, which is being developed for debridement of chronic and other hard-to-heal wounds. NexoBrid and EscharEx are based on its proteolytic enzyme technology. The firm is also developing an injectable product based on its proteolytic enzyme technology for connective tissue pathologies and indications.
Revenue Growth: MediWound reported third quarter revenue of $5.4 million, up 23% year-over-year, fueled primarily by increased development services, including Department of Defense contracts.
EscharEx Progress: Enrollment in the Phase III VALUE trial for EscharEx (venous leg ulcers) continues, with most sites now active. An updated market analysis estimates $831 million in annual peak U.S. sales, up from $725 million, due to higher pricing assumptions.
NexoBrid Expansion: The expanded NexoBrid manufacturing facility is now commissioned, increasing production capacity sixfold, with full operational status expected by year-end 2025.
BARDA Contract Update: A long-term BARDA contract is pending following a government RFP; activities paused during the U.S. shutdown but are expected to resume soon.
Financial Position: MediWound closed a $30 million equity financing, ending the quarter with $60 million in cash and equivalents, strengthening its ability to fund growth.
